Evidence-Based Complementary and Alternative Medicine

Research Article

Jianpi Bushen, a Traditional Chinese Medicine Therapy, Combined with Chemotherapy for Gastric Cancer Treatment: A Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of included studies.


Included trials	Sample size (T/C)		Age (T/C)		Cancer stage	Intervention	Treatment course (C/W/D)	KPS

Gu et al., 2012	46	48	51.7	58.4	-	FEJ + TCF, DC, FOLFOX4, DCF	1 C, 4 W/C	>60
Nan and Yang, 2007	130	86	18–75		III-IV	BJD + MFV	1 C, 6 W/C	≥60
Zhang et al., 2010	30	30	45.2 ± 12.1	46.3 ± 11.8	-	BJD + PTX, OXA, CF, 5-FU	2–4 C, 14 D/C	-
Li, 2008	16	16	53.2	53.6	-	JBD + TF	2 C, 3 W/C	≥70
G. Q. Zhao and J. Z. Zhao, 2008	38	32	59.1 ± 9.4	57.8 ± 8.2	I–III	JBD + MFP	4 C, 28 D/C	-
Le et al., 2015	45	45	62.5 ± 5.5	61.7 ± 5.8	II–IV	JBD + FOLFOX4	4 C, 14 D/C	≥60
Zhang et al., 2012	46	46	45.35 ± 6.7	48.35 ± 7.2	I–IV	JBD + PTX, CF, 5-FU	4 C, 2 W/C	≥60
Zhang et al., 2016	30	30	48.52 ± 4.58	45.52 ± 5.58	II-III	JBD + FOLFOX4	6 C, 1 W/C	-
Du et al., 2011	120	120	55.2		IV	JBD + FOLFOX4	2 C, 21 D/C	≥60
Wang and Liu, 2015	30	30	70.2 ± 2.3	72.6 ± 2.1	III-IV	JBD + EPI, DDP, CAP	4 C, 10 D/C	≥60
Zheng et al., 2012	35	30	64	63	IIIB-IV	JBD + L-OHP, 5-FU/CF	2 C, 21 D/C	≥60
Guo et al., 2015	121	118	73.1 ± 4.4	74.1 ± 4.0	III-IV	JBD + XELOX	6 C, 3 W/C	≥60
Huang et al., 2010	20	20	46.7 ± 11.9	45.3 ± 12.5	-	JBD + 5-FU, CF, DDP/PTX	2–4 C, 2 W/C	-
Mo and Xiao, 2008	32	32	47.5 ± 8.6	48.3 ± 7.9	I–IV	JBD + FLP	4 C, 28 D/C	>60
Lin and Wu, 2007	30	20	24~65		-	JBD + PTX, CF, FU	4 C, 2 W/C	-
Tian and Han, 2011	42	39	56.83 ± 8.74	55.72 ± 7.32	-	JBD + DOC, DDP	2 C, 21 D/C	≥60
Lai et al., 2010	25	30	44	48	-	JBD + TAX, 5-FU, CF	4 C, 10 D/C	≥50
Huang and Xu, 2015	45	45	62.5 ± 5.5	61.7 ± 5.8	-	JBD + tegafur	1 C, 4 W/C	≥60
Sun et al., 2009	414	255	-		-	JBD + CTX	6 C, 4 W/C	-
Bu et al., 2013	30	30	48	49	III A-IV	FEJ + XELOX	3 C, 3 W/C	≥60
Cui et al., 2015	30	30	61	57.5	-	JBD + TAX, DDP	6 C, 3 W/C	-
Zhao and Zhang, 2012	38	32	69.7	71.3	III-IV	JBD + L-OHP, 5-FU	3 C, 2 W/C	>50
Ning et al., 1985	180	146	51		III-IV	JBD + MMC, 5-FU, VCR	1 C, 6 W/C	-
Wang et al., 2016	40	38	32–75	35–73	II-IIIA	JBD + FOLFOX4	12 C, 4 W/C	≥80
Liu, 2010	69	34	25–84	32–82	II-III	JBD + FOLFOX4	6–8 C, 2 W/C	>60
Chen and Wang, 1996	40	20	58	60	II-III	JBD + 5-FU, MMC, ADM	1 C, 6 W/C	-

Note. T/C: treatment group/control group; C: cycle; W: week; D: day; KPS: Karnofsky; FEJ: Compound E Jiao Jiang; TCF: PTX (paclitaxel) and DDP (cisplatin) and 5-Fu (5-fluorouracil); DC: DOC (docetaxel) and DDP; FOLFOX4: OXA (oxaliplatin) and CF (calcium folinate) and 5-Fu; DCF: DOC and DDP and 5-Fu; BJOL: bushenjianpi oral liquid; MFV: MMC (mitomycin) and 5-Fu and VCR (vincristine); BJD: bushenjianpi decoction; JBD: Jianpi Bushen decoction; TF: PTX and 5-Fu; MFP: 5-Fu and MMC and DDP and CF; EPI: pirarubicin; CAP: capecitabine; L-OHP: oxaliplatin; XELOX: OXA and CAP; FLP: CF and 5-Fu and DDP; FU: fluorouracil; CTX: cytoxan; TAX: paclitaxel; VCR: leurocristine; ADM: doxorubicin. treatment group was given JPBS Chinese medicine combined with chemotherapy, and the control group was given only chemotherapy.